Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: AI-generated image
The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.
The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.
RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.
The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.
Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.
Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.
Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.
The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.
According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.
Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.
The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.
Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients
The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.
The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.
Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.
Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.
The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.
Credit: AI-generated image
Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.
The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.
According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.
The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.
According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."
However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.
The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.
Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction
The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:
Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.
Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know
Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.
"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.
Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.
Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.
Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).
Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests
Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.
The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.
The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.
Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.
Credit: iStock
Could chewing gum one day help fight cancer? Researchers at the University of Pennsylvania in the US have developed an experimental gum made from lablab beans, also known as Indian beans, that targets human papillomavirus (HPV) and harmful oral bacteria associated with head and neck cancer.
In laboratory tests using oral samples from cancer patients, extracts of the gum reduced HPV levels by up to 93%. An enhanced version also reduced two harmful bacterial species to nearly undetectable levels without affecting the beneficial bacteria tested.
The experimental gum builds on the team's earlier research into lablab beans. It contains FRIL, a naturally occurring plant protein with antiviral properties.
Researchers tested gum extracts against microorganisms in oral samples collected from patients with head and neck cancer.
The results published in Scientific Reports journal showed:
The researchers also developed an enhanced version containing protegrin, an antimicrobial peptide. Peptides are short chains of amino acids, the building blocks of proteins.
A single dose of the enhanced gum extract reduced two targeted bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn), to nearly undetectable levels.
Also read: HPV Vaccines Can Prevent Head And Neck Cancers In Men, Says Study
The experimental formulation selectively targeted harmful bacteria while leaving the beneficial bacterial populations examined in the study largely unaffected.
The oral microbiome, which consists of microorganisms living inside the mouth, plays an important role in maintaining oral health.
Cancer treatments such as radiation therapy can disrupt this microbial balance, reducing beneficial bacteria and encouraging the growth of potentially harmful microorganisms, including Candida albicans, a type of yeast.
The researchers suggest that selectively targeting harmful microbes while preserving beneficial ones could be particularly useful for patients undergoing cancer treatment.
Read More: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours
The researchers believe the findings warrant further investigation through human clinical trials. They envision the technology potentially being used alongside existing cancer treatments or as a preventive approach to limit infections.
"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said.
He said the findings support advancing these therapies into clinical trials as additional treatments or as prophylaxis to prevent infection and transmission.
Prophylaxis refers to measures taken to prevent a disease or infection before it occurs.
The plant-based technology could also offer a potentially affordable way to deliver protective proteins directly into the mouth.
However, the findings should be interpreted cautiously. The researchers tested gum extracts on patient samples under laboratory conditions. They have not established whether chewing the gum produces the same results in people or whether reducing these microorganisms can prevent cancer or improve treatment outcomes.
Human clinical trials will be needed to establish its safety and effectiveness. For now, the bean-based gum remains experimental and is not a proven cancer-prevention or treatment option.
© $2026 Times Horizon Private Limited